Boston Scientific Corporation (NYSE:BSX) is one of the most promising healthcare stocks according to Wall Street analysts.
On June 4, Truist Securities lowered its price target on Boston Scientific Corporation (NYSE:BSX) from $85 to $64, while keeping its Buy rating on the stock
Richard Newitter, the analyst on record, cited a growing slowdown in demand for the company’s Watchman heart device. Copyright: nimon / 123RF Stock Photo The Watchman is a small implant inserted into the heart to prevent blood clots from forming and traveling to the brain. In other words, the device is designed to reduce the risk of stroke in patients with non-valvular atrial fibrillation (AFib).
It serves as a one-time alternative to lifelong blood thinners. According to Newitter, the trouble began building when Boston Scientific’s Q4 2025 results showed that Watchman sales came in about 1% below analyst expectations. Then when Boston Scientific CEO Michael Mahoney spoke at Bernstein’s annual conference on May 27, he disclosed that doctors were increasingly opting to combine Watchman procedures with other cardiac treatments in a single appointment rather than scheduling them as standalone procedures.